Verve Therapeutics, Inc. develops gene editing medicines for cardiovascular diseases, including VERVE-101, a single-course gene editing treatment that turns off the PCSK9 gene, and the ANGPTL3 program. The company has collaborations and licensing agreements with Beam Therapeutics Inc., Acuitas Therapeutics, Inc., The Broad Institute, and the President and Fellows of Harvard College. Incorporating in 2018 as Endcadia, Inc., Verve Therapeutics, Inc. is based in Cambridge, Massachusetts.